Tango Therapeutics, Inc. 8-K

What Happened

• Tango Therapeutics (TNGX) filed an 8-K reporting that Daniella Beckman will no longer serve as the company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective April 15, 2026.
• The board appointed Matthew Gall as Chief Financial Officer and principal financial officer, also effective April 15, 2026. The company also appointed Jessica Newcomb as principal accounting officer effective the same date. A press release announcing these leadership changes was issued April 15, 2026.

Key Details

• Effective date: April 15, 2026 (appointments and CFO departure).
• New CFO Matthew Gall, age 49, most recently served as CFO of Kalaris Therapeutics (Nov 2025–Apr 2026); previously CFO at iTeos Therapeutics (Jun 2020–Aug 2025) and held roles at Sarepta Therapeutics (2012–2020). Education: B.S. (Bowling Green State) and MBA (Chicago Booth).
• Compensation highlights for Mr. Gall per his employment agreement: $540,000 annual base salary and a target cash bonus of 40% of base salary (prorated for partial years).
• Equity grants: option to purchase 240,000 shares under the 2023 Inducement Plan (exercise price = Nasdaq closing price on May 1, 2026); option vests 25% after one year, then monthly over the following 36 months. Plus 40,000 restricted stock units vesting in three roughly equal annual installments.
• Jessica Newcomb (age 40), promoted to principal accounting officer; she is SVP, Finance, a CPA in Massachusetts, joined Tango in Aug 2022 and previously served as VP, Corporate Controller at Acceleron Pharma.

Why It Matters

• Leadership continuity: the company has named an experienced biotech finance executive as CFO and elevated an existing senior finance officer to the principal accounting role, which supports continuity in financial leadership and reporting.
• Costs and dilution: the new CFO’s cash compensation and equity awards increase recurring payroll obligations and will add potential share dilution if equity vests and is exercised. The option exercise price will be set to the Nasdaq close on May 1, 2026 (filing does not state the dollar price).
• Governance and disclosure: the appointment and related employment agreement are documented in the 8-K, and Tango issued a press release the same day to inform investors.